

PATIENT DETAILS

*Affix patient Addressograph if available

SURNAME: _____ FIRSTNAME(S): _____

DATE OF BIRTH: ____/____/____ MRN: _____



NMDS Multiple Sclerosis Patient Eligibility Form Ocrelizumab (Ocrevus®)

Form must be completed in full and saved securely in the patient's medical record for audit purposes only

TREATMENT	HSE APPROVED INDICATION	ICD10	Protocol Code
Ocrelizumab (Ocrevus®)	Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	G35	MS102
	OR		
	Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.	G35	MS103

ELIGIBILITY		YES	NO
Indication as per protocol MS102 (RMS) or protocol MS103 (PPMS)			
Eligibility criteria in protocol MS102 or MS103 have been met			
EXCLUSIONS		YES	NO
All contraindications laid out in protocol MS102 or protocol MS103 (PPMS) have been considered.			
PREVIOUS MEDICATION(S) FOR MULTIPLE SCLEROSIS			
Name of Medicine (in order of use; 1. = first line etc.)	Reason for change in treatment (please tick)		
	Adverse Event	Loss of Response	Other Reason
1.			
2.			
3.			
4.			
5.			
PRESCRIBER DETAILS			
Prescriber Name			
Medical Registration Number			
ELIGIBILITY FORM COMPLETED BY			
Name			
Date			

Protocol: MS - Ocrelizumab	Published: 16/10/2020 Update: January 2022 Review: January 2024	Version Number: 2
AHDMP Protocol Code: MS102 and MS103	Contributor: Prof Christopher McGuigan as Multiple Sclerosis Lead for the National Clinical Programme for Neurology	Page 1 of 1
<p>The information contained in this document is a statement of consensus from the National Clinical Programme for Neurology regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p>This information is valid only on the day of printing, for any updates please check https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/ndms/</p>		